Rational Pharmacotherapy in Cardiology

Advanced search

Assessment of the Adequacy of Drug Choice in Patients with Acute Myocardial Infarction According to the PROFILE-IM Registry

Full Text:


Background. The prognosis for patients after acute myocardial infarction (AMI) can be improved by prescribing beta-blockers (BB), angiotensin converting enzyme inhibitors (ACEI) and statins. This is reflected in the current clinical guidelines, in which these drugs are considered mandatory for almost all patients after AMI. However, not all representatives of the same drug class have the same evidence base in relation to the impact on the outcomes of AMI, in addition, not all BB and ACEI, according to the official instructions have the indication "recent AMI".

Aim. To assess the adequacy of the choice of BB, ACEI and angiotensin receptor antagonists (ARA), prescribed after recent AMI, using the materials of the prospective registry PROFILE-IM.

Material and methods. 1 60 patients after AMI referred to outpatient clinic from March 01,2014 to June 30, 201 5 were included into the registry. The therapy prescribed to patients at discharge from the hospital and at the first visit to the outpatient clinic were evaluated, special attention was paid to three classes of drugs: BB, ACEI/ARA.

Results. The majority of patients were recommended ACEI/ARA (88.1%) and BB (98.8%) at discharge from hospital. Not prescribing of these groups of drugs in about half of the cases had a reasonable cause, for ACEI/ARA in 13 patients (8.1%) the cause could not be clarified. When choosing a BB in most cases (both in hospital and in the outpatient clinic) preference was given to bisprolol (61% and 67%, respectively), which has no evidence of prognosis improvement for patients after AMI, the second place took metoprolol, its prescription was two times less than bisprolol. When choosing ACEI, priority was given to perindopril, with which no one randomized clinical trial was carried out in patients after AMI (38% of prescriptions in the hospital and 41% - in the outpatient clinic). Enalapril took the second place (20% and 22%, respectively), the remaining ACEI were prescribed much less frequently, ARA were also prescribed rarely (5%).

Conclusion. After AMI the majority of patients were prescribed BB, ACEI/ARA, which in accordance with current clinical guidelines are necessary to improve long-term outcomes. However, the choice of a specific drug within the drug class not always consistent with evidence-based medicine, current clinical guidelines and the official instructions for the medical use. In this regard, patients after AMI do not receive all the benefits of drug therapy to improve long-term outcomes.

About the Authors

S. Yu. Martsevich
National Medical Research Center for Preventive Medicine
Russian Federation

Sergey Yu. Martsevich - MD, PhD, Professor, Head of Department of Preventive Pharmacotherapy.

Petroverigsky per. 1 0, Moscow, 101990

N. P. Kutishenko
National Medical Research Center for Preventive Medicine
Russian Federation

Natalia P. Kutishenko - MD, PhD, Head of the Laboratory for Pharmacoepidemiological Research, Department of Preventive Pharmacotherapy.

Petroverigsky per. 1 0, Moscow, 101990

E. P. Kalaydzhyan
Moscow City Polyclinic No9
Russian Federation

Elena P. Kalaydzhyan - MD, Cardiologist.

Perervinsky bulv. 4, Moscow, 109451

D. P. Sichinava
Moscow City Polyclinic No9
Russian Federation

David P. Sichinava - MD, Cardiologist.

Perervinsky bulv. 4, Moscow, 109451

V. A. Evdakov
Federal Research Institute for Health Care Organization and Informatics
Russian Federation

Valeryan A. Evdakov - MD, PhD, Professor, Head of Department of Scientific Foundations of the Ambulatory Care Organization.

Dobrolyubova ul. 11, Moscow, 127254


1. Martsevich S.Y, Ginzburg M.L., Kutishenko N.P. et al. Lyubertsy mortality study (LMS): factors influencing the long-term survival after myocardial infarction. Profilakticheskaya Meditsina. 2013;16(2):32-8 (In Russ.)

2. O'Gara P.T., Kushner FG., Ascheim D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61 :e78-140. doi:10.1016/j.jacc.2012.11.019.

3. Martsevich S.Yu., Kutishenko N.P., Anichkov D.A., et al. National recommendations on rational pharmacotherapy of patients with cardiovascular diseases. Cardiovascular Therapy and Prevention 2009;8(6) Suppl 4:2-56 (In Russ.)

4. . Martsevich S.Yu., Kutishenko N.P., Tolpygina S.N., et al. National guidelines for the efficacy and safety of drug therapy in primary and secondary prevention of cardiovascular diseases. VNOK Recommendations, 2011. Rational Pharmacotherapy in Cardiology 2011 ;7(5):1 -72 (In Russ.) doi:10.20996/1819-6446-2011-7-5.

5. Furberg C.D., Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol. 2001;37:1456-60. doi :10.1016/S0735-1097(01)01161-5.

6. Martsevich S.Yu., Kutishenko N.P., Sichinava D.P., et al. Prospective outpatient registry of myocardial infarction patients (PROFILE-IM): study design and first results. Cardiovascular Therapy and Prevention. 2018;17(1 ):81 -6 (In Russ.) doi:10.1 5829/1728-8800-2018-1-81-86.

7. Holms D.R., Becker J.A, Granger C.B. et al. ACCF/AHA health policy statement on therapeutic interchange and substitution. Circulation. 2011 ;124:1290-310. doi:10.1161/CIR.0b013e31822d97d5.

8. Blochl-Daum B. "Me-too drugs" and the concept of a class effect. Wien Med Wochenschr 2006;1 56:494-7. doi:10.1007/s10354-006-0333-2.

9. Beta-blocker Heart Attack Trial Research Group (BHAT). A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1 707-1 4. doi:10.1001/jama.1982.03320370021023.

10. Freemantle N., Cleland J., Young P. et al. |3-Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-7.

11. Martsevich S.Yu. The use of angiotensin converting enzyme inhibitors after myocardial infarction. What do evidence-based medicine data speak for? Rational Pharmacotherapy in Cardiology 2010;6(5):673-6 (In Russ.) doi:10.20996/1819-6446-2010-6-5-673-676,

12. Harris M., Taylor G., Jackson D. Clinical evidence made easy Emerg Nurse. 2014;22(6):10. doi: 10.7748/en.22.6.10.s13.

13. Smith S.C. Evidence-based medicine: making the grade miles to go before we sleep. Circulation. 2006;113:178-9. doi:10.1161/CIRCULATIONAHA.I05.592238.

14. Mant D. Can randomised trials inform clinical decisions about individual patients? Lancet. 1999;353:743-6. doi:10.1016/S0140-6736(98)09102-8.

15. Lee H.Y, Cooke C.E., Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm. 2008;14(3):271-80. doi:10.18553/jmcp.2008.14.3.271.


For citations:

Martsevich S.Yu., Kutishenko N.P., Kalaydzhyan E.P., Sichinava D.P., Evdakov V.A. Assessment of the Adequacy of Drug Choice in Patients with Acute Myocardial Infarction According to the PROFILE-IM Registry. Rational Pharmacotherapy in Cardiology. 2019;15(2):224-229. (In Russ.)

Views: 458

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)